Other anticancer or experimental therapy; no other experimental therapies (including chemotherapy, radiation, hormonal treatment, antibody therapy, immunotherapy, gene therapy, vaccine therapy, angiogenesis inhibitors, matrix metalloprotease inhibitors, thalidomide, anti-vascular endothelial growth factor [VEGF]/fetal liver kinase  [Flk-] monoclonal antibody or other experimental drugs) of any kind are permitted while the patient is receiving study treatment
Use of any other experimental medication(s) within  days prior to start of the study treatment.
Use of any other experimental drug or therapy within  days of starting treatment with abatacept
Use of any other experimental drug or therapy within  days prior to first dose
Treatment with an experimental therapy within the last  days
Participant has used experimental therapy for acute GVHD within  weeks of randomization. If unsure of the definition of \experimental\, discussion with one of the protocol chairs is recommended.
Concurrent treatment with other experimental treatments for NSCLC while on the study
Prior treatment with radium- dichloride or any experimental radiopharmaceutical.
Experimental therapies within  weeks before first ZW dosing
Involved in other experimental protocols (except with permission of the other study PI)
Use of experimental drug within  weeks of treatment
The time from the last dose of the most recent chemotherapy or experimental therapy to the first dose of study drugs is <  times the half-life of the previously administered agent(s).
Other concurrent experimental therapies
Patients may have received treatment of completely resected early stage melanoma, comprising interferon, radiation treatment, or experimental vaccine therapy, and in the metastatic setting patient can have had treatment such as chemotherapy, immunotherapy (except prior treatment with ipilimumab and IL-), and other experimental agent which was completed  weeks prior to enrollment
Participants who have already received anti-VEGF or experimental antiangiogenic therapy for glioblastoma
Use of any other experimental drug or therapy within  days of baseline
Patients receiving other experimental immunotherapy
Receiving another experimental drug within  weeks of initiation of conditioning (day -) unless approved by the PI
Use of any other experimental drug or therapy within  days of baseline.
Seronegative for human immunodeficiency virus (HIV) antibody. (The experimental treatment being evaluated in this protocol depends on an intact immune system. Patients who are HIV seropositive can have decreased immune-competence and thus may be less responsive to the experimental treatment and more susceptible to its toxicities.)
Concurrent opportunistic infections (The experimental treatment being evaluated in this protocol depends on an intact immune system. Patients who have decreased immune-competence may be less responsive to the experimental treatment and more susceptible to its toxicities).
Anticancer treatment within designated period before enrollment including\r\n* Minor surgical procedure (such as biliary stenting) within  days\r\n* Major surgical procedure or radiation treatment within  days\r\n* Chemotherapy or experimental drug treatment with published half-life known to be  hours within  days\r\n* Experimental drug treatment with unpublished or half-life greater than  hours within  days\r\n* Radiotherapy for measurable lesions delivered in a normal organ-sparing technique within  days (except for palliative radiotherapy)
Concomitant therapy with any other experimental drug
Seronegative for human immunodeficiency virus (HIV) antibody; (the experimental treatment being evaluated in this protocol depends on an intact immune system; patients who are HIV seropositive can have decreased immune competence and thus may be less responsive to the experimental treatment and more susceptible to its toxicities)
Concurrent opportunistic infections (the experimental treatment being evaluated in this protocol depends on an intact immune system; patients who have decreased immune competence may be less responsive to the experimental treatment and more susceptible to its toxicities)
Patients must not be scheduled to receive another experimental drug while on this study.
Patients must not be scheduled to receive another experimental drug while on this study
Washout period of at least  days after any approved or experimental tumor directed therapy prior to start of cyclophosphamide and fludarabine
Patients who have been treated with any investigational drug within  days prior to the first dose of study medication, or who are receiving concurrent treatment with other experimental drugs or anti-cancer therapy
Prior experimental therapy within  days of enrollment
Prior experimental therapy within  weeks of planned start of this trial
Receiving other experimental therapy
Patients must not be scheduled to receive another experimental drug while on this study
Prior use of experimental agents for prostate cancer
Participants must be more than  days removed from most recent minor surgical procedure (such as biliary stenting),  days from most recent major surgical procedure,  days removed from most recent radiation therapy, chemotherapy or experimental drug treatment with published half-life known to be  hours or less and  days removed from last experimental drug treatment with unpublished or half-life greater than  hours
Concurrent opportunistic infections (the experimental treatment being evaluated in this protocol depends on an intact immune system; patients who have decreased immune competence may be less responsive to the experimental treatment and more susceptible to its toxicities)
Prior experimental therapy within  days of planned start of this trial
Use of any other experimental drug or therapy within  days of baseline
Patients who have received experimental agents within  weeks of study entry
Use of any other experimental drug or therapy =<  days prior to registration on this study; NOTE: Patients on low dose prednisone (=<  mg) for treatment of conditions other than CLL are eligible
Patients who are currently receiving any other experimental agent, must have stopped other experimental agents at least  days prior to st study dose
Experimental therapy within  weeks prior to first dose of study drug treatment on Study Day  of Period A
Involved in other experimental protocols (except with permission of the other study PI)
Use of any other experimental drug or therapy within  days of baseline
Patients must not be scheduled to receive another experimental drug while on this study
Patients who have taken part in an experimental drug study within  weeks of initiating study treatment with sonidegib
Patients who have taken part in an experimental drug study =<  weeks prior to registration
For the MF and MDS/MPN-U arms (arms  & ), use of any other standard drug (except hydroxyurea, anagrelide, growth factors, Revlimid, clofarabine, etc) or experimental drug or therapy within  days of starting study therapy
Use of any other experimental drug or therapy within  days of study-related drug therapy
Patient should not be getting any other experimental therapy for aGvHD
Serology:\r\n* Seronegative for human immunodeficiency virus (HIV) antibody (the experimental treatment being evaluated in this protocol depends on an intact immune system; patients who are HIV seropositive may have decreased immune-competence and thus be less responsive to the experimental treatment and more susceptible to its toxicities)
Concurrent opportunistic infections (the experimental treatment being evaluated in this protocol depends on an intact immune system; patients who have decreased immune-competence may be less responsive to the experimental treatment and more susceptible to its toxicities)
Use of any other experimental drug or therapy within  days of baseline
Use of any other experimental drug or therapy =<  days prior to registration
Use of any other experimental drug or therapy within  days of baseline.
patients participation in other pharmaco therapeutic program with an experimental therapy that is known to effect the coagulation system;
Patient is receiving everolimus in combination with an unapproved or experimental treatment
Previous cytotoxic drug therapy, non-cytotoxic drug therapy, or experimental drug therapy directed against the brain tumor. Subjects who received Gliadel wafers will be excluded.
Any other experimental treatment on another clinical trial
Concurrent opportunistic infections (The experimental treatment being evaluated in this protocol depends on an intact immune system. Patients who have decreased immune competence may be less responsive to the experimental treatment and more susceptible to its toxicities)
Concurrent treatment with other experimental drugs or any other systemic anticancer therapy (due to unknown drug-vaccine potential interactions)
Subject is receiving or is less than  days since ending other experimental drug (no marketing authorization for any indication)
 weeks from prior experimental drug
No other experimental therapy is permitted while on study
Receiving another experimental drug within  weeks before initiation of conditioning (day -)
Patient must have no plans to receive any other experimental therapy while on the protocol treatment; previous experimental therapy must have been completed at least  days prior to registration
Therapeutic or experimental monoclonal antibodies within  day or prior radiation therapy within  days of the first dose of study drug.
Prior AML or ALL therapy (non-experimental) within  days of first dose of ONO- (except those permitted in the protocol)
Planned treatment with other experimental drugs or any other non-hormonal anti-cancer therapy;
Use of any other experimental drug or therapy within  days of baseline
Use of any other standard or experimental therapy within  days of starting study therapy
Prior treatment with another experimental anti-tumor vaccine is permissible
No experimental medications within  days of study entry
Other experimental drugs =<  weeks prior to registration
Seronegative for human immunodeficiency virus (HIV) antibody; the experimental treatment being evaluated in this protocol depends on an intact immune system; patients who are HIV seropositive can have decreased immune function and thus are likely less responsive to the experimental treatment
Use of any standard/experimental anti-lymphoma drug therapy, including steroids (dexamethasone dose >=  mg/day or prednisone >=  mg/day), within  weeks of initiation of the study or use of any experimental non-drug therapy (e.g., donor leukocyte/mononuclear cell infusions) within  days of initiation of the study drug treatment; hydroxyurea is permitted up to  hours before the first dose of study drug in patients with rapidly-proliferating disease
Other concurrent experimental or investigational drugs
Use of any standard/experimental anti-lymphoma drug therapy, including steroids, within  weeks of initiation of the study or use of any experimental non-drug therapy (e.g., donor leukocyte/mononuclear cell infusions) within  days of initiation of the study drug treatment
No experimental intravesical therapy within  weeks of study entry
For subjects with recent chemotherapy or experimental therapy the first dose of study drug must occur after  times the half-life of the agent(s).
For subjects with recent chemotherapy or experimental therapy the first dose of study drug must occur after  times the half-life of the agent(s).
COHORT A: Concomitant therapy with any other experimental drug
COHORT B: Concomitant therapy with any other experimental drug
Patient is currently participating in other experimental studies that could affect the primary endpoint (e.g. experimental chemotherapy regimen).
Experimental medications within the last  weeks prior to day 
Use of any standard/experimental anti-lymphoma drug therapy, including steroids, within  weeks of initiation of the study or use of any experimental non-drug therapy (e.g., donor leukocyte/mononuclear cell infusions) within  days of initiation of the study drug treatment; prior allogeneic stem cell transplant (SCT) within  weeks or autologous SCT within  weeks of initiation of therapy
Use of any other experimental drug or therapy within  days of baseline
Treatment with any known therapeutic or experimental therapy within  weeks prior to enrollment, or currently participating in any other interventional clinical study
Concomitant use of other anticancer (except for corticosteroids) or experimental agents
Have received antimyeloma treatment, radiotherapy, or any experimental drug or therapy within  weeks before the first infusion
Receipt of an experimental vaccine within  months or in the opinion of the Investigator is responding to an experimental vaccine given within  months, or has received any previous gene therapy using an integrating vector
Concomitant therapy with any other experimental drug
Use of any other experimental drug or therapy within  days of baseline
Use of any other experimental drug or therapy within  days of baseline.
Subjects on any other systemic therapy for cancer, including any other experimental treatment
Any experimental therapy ?  days prior to randomization
Patient has used any other anti-cancer drug or therapy, including experimental, within  days of initiation of lenalidomide treatment (radiation therapy is allowed within  days)
Use of any other experimental drug or therapy within  days of baseline
Use of any other experimental drug or therapy other than carfilzomib and pomalidomide within  days of treatment start on this protocol
Use of any other experimental anti-cancer drug or therapy within  days of initiation of the study drug
Use of experimental drugs ?  days prior to screening
Any experimental imaging agent directed at amyloid within  weeks
Antileukemia or experimental treatment within  weeks of study drug (other than hydroxyurea or -mercaptopurine)
Use of any experimental immunotherapy.
Undergoing stapled anastomosis with the use of an experimental or non-FDA approved stapler.
Prior treatment with a licensed or experimental smoothened inhibitor.
Pregnant patients may not receive this experimental therapy
Another experimental anti-amyloid therapy other than NEOD within  years
Receiving other experimental therapy
Use of any experimental immunotherapy.
 weeks from prior experimental drug
Use of any standard/experimental anti-lymphoma drug therapy, including steroids, within  weeks of initiation of the study or use of any experimental non-drug therapy (e.g. donor leukocyte/mononuclear cell infusions) within  days of initiation of the study drug treatment; prior allogeneic stem cell transplant (SCT) within  weeks or autologous SCT within  weeks of initiation of therapy
Have received experimental therapy within  weeks of enrollment
Experimental therapy within  weeks prior to first dose of study-drug treatment in Cycle 
Use of any other experimental drug or therapy within  days of baseline
Use of any other standard or experimental therapy within  days of starting study therapy
Currently receiving any other experimental therapy or has received any other experimental therapy within the  weeks prior to enrollment
Treatment with an experimental drug within  days of first dose
Use of any other experimental drug or therapy within  days of baseline
Received any experimental non-drug therapy (e.g., donor leukocyte/mononuclear cell infusions) within  days of entry
Patients who have taken part in an experimental drug study within  weeks of initiating treatment with LDE
At least  days must have elapsed since any prior experimental therapy
Use of any other experimental drug or therapy within  days of baseline
Use of any other experimental drug or therapy within  days prior to randomization
Seronegative for human immunodeficiency virus (HIV) antibody; Note: The experimental treatment being evaluated in this protocol depends on an intact immune system; patients who are HIV seropositive can have decreased immune competence and thus may be less responsive to the experimental treatment
Experimental therapy within  weeks prior to first dose of study drug
Patients must be enrolled in a Phase  clinical trial and be within  weeks of starting the experimental therapy or intervention
Subject is receiving or is less than  days since ending other experimental device or drug (no marketing authorization for any indication)
Use of any other experimental drug or therapy within  days of baseline
Involved in other experimental protocols except with permission of other PI
Experimental immunotherapies:  months
Involved in other experimental protocols (except with permission of the other study PI)
Involved in other experimental protocols (except with permission of the other study PI)
Patients participating treatment trials including targeted therapy, experimental therapy or immunotherapy are also eligible
Subjects may not be receiving any experimental therapies
Treatment with any experimental therapy within  days prior to enrollment or current participation in any other interventional clinical study
Donors receiving experimental therapy or investigational agents.
Experimental therapy within  weeks prior to first dose of study drug treatment in Cycle 
